pancreatic cancer
supportive care
palliative care

Palliative Care Consultation Associated With Less Aggressive End-of-Life Care in Advanced Pancreas Cancer

In a study reported in the Journal of the National Cancer Institute, Jang et al found that palliative care consultation was associated with decreased use of chemotherapy near death and lower risks of ICU admission, multiple emergency department visits, and multiple hospitalizations near death in...

pancreatic cancer

Study Shows Targeting Cancer Cell ‘Cloak’ Could Benefit Drug Delivery

Cancer cells can cloak themselves within tumors by hiding behind a dense layer of cellular stroma. According to a new study by the Translational Genomics Research Institute (TGen), drugs that target and strip away the stroma would pave the way for other drugs to reach the cancerous cells within the ...

lung cancer
pancreatic cancer
issues in oncology

Chemotherapy Trials for Advanced Cancers of the Lung and Pancreas Overestimate Survival for Elderly Medicare Patients

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic cancer and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Lamont et al reported...

pancreatic cancer

Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States

In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...

issues in oncology
pancreatic cancer
issues in oncology

Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions

Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...

cns cancers
pancreatic cancer
issues in oncology
sarcoma

Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors

Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...

issues in oncology
cns cancers
cns cancers
pancreatic cancer
issues in oncology
solid tumors

ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors

A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...

pancreatic cancer

Prime-Boost Vaccine Increases Survival in Metastatic Pancreas Cancer

In a study reported in the Journal of Clinical Oncology, Le et al found that adding Listeria monocytogenes–expressing mesothelin (CRS-207) boost to GVAX pancreas vaccine priming resulted in improved overall survival in patients with previously treated metastatic pancreas adenocarcinoma....

hepatobiliary cancer
pancreatic cancer

Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers

The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...

pancreatic cancer

Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin

Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium  (Abstract 234). The primary analysis ...

pancreatic cancer

Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost

A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...

pancreatic cancer

Addition of Hypoxia-Activated Prodrug TH-302 to Gemcitabine Improves Progression-Free Survival in Advanced Pancreas Cancer

TH-302 is a hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. In a phase II trial reported in the Journal of Clinical Oncology, Borad et al found that the addition of TH-302 to gemcitabine improved progression-free survival in patients...

pancreatic cancer

Long-Term Diabetes Associated With Increased Mortality in Pancreas Cancer

In a study reported in the Journal of Clinical Oncology, Yuan et al found that pancreas cancer patients with diabetes of more than 4 years’ duration at diagnosis had significantly poorer survival compared with nondiabetic patients. Study Details The study involved data from 1,006 patients...

pancreatic cancer

Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...

hepatobiliary cancer
pancreatic cancer

Regional Hepatopancreaticobiliary Surgical Program Improves Care in VA System

In a retrospective cohort study reported in JAMA Surgery, Lau et al found that implementation of a multidisciplinary hepatopancreaticobiliary surgical program in a Veterans Affairs (VA) health-care region resulted in improved care and outcomes. The study involved analysis of practices and outcomes ...

pancreatic cancer

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme Therapeutics is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and...

cns cancers
pancreatic cancer

ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors

In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...

pancreatic cancer

Boost in Plasma Levels of Chain Amino Acids Is Associated With Increased Risk of Pancreatic Cancer

In a recent study reported in Nature Medicine, scientists from Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and the Harvard School of Public Health, among other institutions, investigated whether pancreatic ductal adenocarcinoma produces metabolic changes that can be...

pancreatic cancer

Baseline Vitamin D Not Associated With Survival in Patients With Advanced Pancreatic Cancer in CALGB 80303/Alliance Trial

Preclinical data indicate a role of vitamin D metabolism in pancreatic tumor development. In a study reported in the Journal of the National Cancer Institute, Van Loon et al found that baseline serum 25-hydroxyvitamin D (25[OH]D) levels were not associated with progression-free survival or overall...

pancreatic cancer
issues in oncology

Genome-Wide Association Study Finds New Genetic Risk Markers in Pancreatic Cancer

A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...

pancreatic cancer

Adding Oxaliplatin to Leucovorin/Fluorouracil Increases Survival in Second-Line Treatment of Gemcitabine-Refractory Pancreatic Cancer

In the German phase III CONKO-003 trial reported in the Journal of Clinical Oncology, Oettle et al found that second-line oxaliplatin, leucovorin, and fluorouracil (5-FU) significantly increased overall survival and time to progression vs leucovorin/5-FU in patients with advanced pancreatic cancer...

pancreatic cancer

No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer

In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...

pancreatic cancer

Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy

The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III trial reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract...

pancreatic cancer
issues in oncology

Daily Low-Dose Aspirin Use May Reduce Risk of Developing Pancreatic Cancer

Men and women who took low-dose aspirin regularly had a 48% reduction in their risk of developing pancreatic cancer, according to a new study. In addition, the longer a person started taking low-dose aspirin, the greater the benefit, ranging from 48% reduction in people who started 3 years before...

pancreatic cancer

Priming Pancreatic Cancer Cells With a Vaccine May Allow Them to Respond to Immunotherapy

Pancreatic ductal adenocarcinoma is considered a “nonimmunogenic” neoplasm and does not typically respond to immunotherapy, in part due to a complex tumor microenvironment that provides a formidable barrier to immune infiltration and function. A new study by Lutz et al has found that by ...

pancreatic cancer

Central Pancreatectomy for Low-Grade Neoplasms Results in 'Excellent' Pancreatic Function but Substantial Morbidity

The availability of cross-sectional imaging has resulted in increased diagnosis of low-grade pancreatic neoplasms and use of central pancreatectomy as an alternative to standard resection for such lesions. In a French single-center experience reported in JAMA Surgery, Goudard et al found that...

pancreatic cancer
issues in oncology

Gene Mutation Found for Aggressive Form of Pancreatic Cancer

Researchers have identified a mutated gene common to adenosquamous carcinoma tumors, the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer. The findings by Liu et al are published in Nature Medicine. Pancreatic cancer is the fourth leading...

pancreatic cancer

Supportive Tumor Tissue Surrounding Cancer Cells Hinders Pancreatic Cancer Progression, Preclinical Study Reports

Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center reported in the journal Cancer Cell. “This supportive tissue that’s...

pancreatic cancer

Early Study Shows Improved Survival With Radioimmunotherapy/Gemcitabine Combination in Patients With Advanced Pancreatic Ductal Cancer

A randomized phase Ib study of a combination of low radiosensitizing doses of gemcitabine and fractionated doses of 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic ductal cancer who had received at least two prior systemic therapies, has found a significant survival advantage in...

pancreatic cancer

Blocking CD47 Signals May Offer New Therapeutic Approach in the Treatment of Pancreatic Cancer

Two preclinical studies of tumor samples taken from 39 patients with pancreatic neuroendocrine tumors and 39 patients with pancreatic ductal adenocarcinoma has found that for both these pancreatic cancers, CD47 is expressed at elevated levels on the cells that make up the bulk of the tumors and on...

pancreatic cancer

Surgical Resection Is Underutilized in Patients With Early-Stage Pancreatic Cancer, Study Finds

Despite the benefits of surgery for early-stage pancreatic cancer, it remains underutilized for patients with this deadly disease, according to a new national analysis of trends and outcomes. Physician-scientists at University Hospitals (UH) Case Medical Center and Case Western Reserve University...

pancreatic cancer

Lab Study Finds Pancreatic Cancer Growth Is Slowed by Blocking the Hhat Enzyme

The overexpression of Hedgehog family proteins contributes to the development of many cancers. Research by Konitsiotis et al has found that blocking the function of the Hedgehog acyltransferase (Hhat) enzyme slows the growth and spread of pancreatic cancer. Targeting inhibition of the Hedgehog...

pancreatic cancer

Study Finds CT Scans Predict Chemotherapy Response in Pancreatic Cancer

Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research published in the Journal of Clinical Investigation by Koay et al, the scans also reflect how well chemotherapy will penetrate the tumor,...

gynecologic cancer
pancreatic cancer
solid tumors

Novel Cancer Vaccine Shows Promise in Ovarian Cancer and Mesothelioma

A novel approach to cancer immunotherapy may provide a new and cost-effective strategy against ovarian cancer and mesothelioma. In a study published in the Journal of Hematology & Oncology, Yuan et al reported that a fusion protein engineered to combine a molecule targeting a tumor-cell-surface ...

issues in oncology
pancreatic cancer

Proteomic Mucin Profiling More Accurate Than Cytology and CEA in Identifying Cystic Precursors of Pancreatic Cancer

Pancreatic cystic lesions are frequently detected radiologic incidentalomas, a considerable proportion of which are pancreatic cancer precursors. In a study reported in the Journal of the National Cancer Institute, Jabbar et al found that proteomic mucin profiling of cyst fluid was more accurate...

issues in oncology
pancreatic cancer

Researchers Identify Biomarker for Noncancerous Pancreatic Cysts

Researchers at the Indiana University School of Medicine have discovered a highly accurate, noninvasive test to identify benign pancreatic cysts, which could spare patients the cost and risk of surveillance or potentially dangerous surgical intervention. The findings are reported in the Journal of...

pancreatic cancer

Immunotherapy Strategy Boosts Survival in Metastatic Pancreatic Cancer

Overall survival was improved in patients with metastatic pancreatic cancer through an innovative immunotherapy strategy in a multicenter study to be reported at the 2014 Gastrointestinal Cancers Symposium (Abstract 177). The results were announced at a press briefing prior to the meeting....

cns cancers
pancreatic cancer

Combination Capecitabine/Temozolomide Appears Highly Effective in Patients With Treatment-Resistant Neuroendocrine Tumors

Interim results from an ongoing phase II clinical trial in patients with various types of advanced neuroendocrine tumors show that a new chemotherapy combination of capecitabine and temozolomide either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after...

issues in oncology
pancreatic cancer

Low hENT1 Is Associated With Poorer Survival in Patients With Pancreatic Cancer Receiving Adjuvant Gemcitabine

In a study reported in the Journal of the National Cancer Institute, Greenhalf et al analyzed the association between human equilibrative nucleoside transporter 1 (hENT1) levels and survival in patients with pancreas cancer receiving adjuvant gemcitabine or fluorouracil (5-FU)/leucovorin after ...

pancreatic cancer

U.S. Pancreatic Cancer Death Rates Increasing in White Adults, Decreasing in Black Adults

In a study reported in Journal of the National Cancer Institute, Jiemin Ma, PhD, MHS, and colleagues from the American Cancer Society investigated trends in pancreatic cancer death rates in the United States between 1970 and 2009. They found that death rates have been increasing in white men and...

pancreatic cancer

Addition of Nab-Paclitaxel to Gemcitabine Improves Survival in Previously Untreated Metastatic Pancreatic Cancer

In a phase III trial reported in The New England Journal of Medicine, Daniel D. Von Hoff, MD, of Translational Genomics Research Institute in Phoenix, and colleagues assessed the addition of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) to gemcitabine in patients with previously untreated...

pancreatic cancer

Investigational Antibody-Drug Conjugate May Provide New Treatment Option for Pancreatic Cancer Patients

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...

pancreatic cancer

Novel Drug Combinations Targeting Pathways Triggered by KRAS May Benefit Patients With Pancreatic Cancer

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented at the AACR-NCI-EORTC...

pancreatic cancer

Long-Term Obesity Is Linked With Poorer Pancreatic Cancer Survival

Although multiple studies have shown that high body mass index (BMI) is associated with an increased risk of developing pancreatic cancer, few studies have evaluated the impact of BMI on survival and none have used prospectively collected data on BMI. Now a large prospective study by Brian M....

pancreatic cancer

Gemcitabine Improves Overall Survival Following Surgery for Pancreatic Cancer

Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in published in the October 9 issue of...

pancreatic cancer

Meta-Analysis Suggests Fluorouracil or Gemcitabine Is Optimum Adjuvant Treatment for Pancreatic Cancer

A meta-analysis reported in The Lancet Oncologyby Wei-Chih Liao, MD, of National Taiwan University Hospital and colleagues indicates that fluorouracil (5-FU) or gemcitabine is optimal adjuvant therapy for pancreatic adenocarcinoma. Chemoradiation was associated with poorer survival and...

issues in oncology
lung cancer
pancreatic cancer

Molecular Marker Predicts Patients Most Likely to Benefit Longest From EGFR Inhibitors

Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...

pancreatic cancer

FDA Approves Nab-Paclitaxel for Late-Stage Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) today expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abraxane) to treat patients with late-stage pancreatic cancer. “Patients with pancreatic cancer are often diagnosed...

pancreatic cancer

Risk of Pancreatic Cancer May Be Reduced by Better Diet

In a study reported in the Journal of the National Cancer Institute, Hannah Arem, MHS, PhD, of the National Institutes of Health, and colleagues analyzed the association between quality of diet according to the 2005 Dietary Guidelines for Americans—Healthy Eating Index 2005...

pancreatic cancer

Researchers Identify Origin of Inflammation-Driven Pancreatic Cancer

Researchers at Mayo Clinic in Florida have revealed the process by which pancreatitis—chronic inflammation of the pancreas—morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients at risk of pancreatic cancer and to potential drug therapies...

Advertisement

Advertisement

;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.